Active	Status	Sponsor type	Region	Phase	Filter
12 Active 12 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tribout, Megan
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec	Recruiting	2	230	US	HDV-Lispro, HDV-L, Lispro, LIS	Diasome Pharmaceuticlas, Inc.	Diabetes Mellitus, Type 1	06/25	12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Active, not recruiting	2	30	Europe, US	SPI-62 dose	Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.	Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic	12/24	12/25
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes	Completed	N/A	319	Canada, US	t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)	Tandem Diabetes Care, Inc., Jaeb Center for Health Research	Type 2 Diabetes Treated With Insulin	09/24	09/24
Roesch, Erica A
NCT06449677: Bionic Pancreas in CFRD	Recruiting	3	150	US	iLet Bionic Pancreas System (BP), Usual Care (UC)	Jaeb Center for Health Research, Cystic Fibrosis Foundation, Massachusetts General Hospital, Beta Bionics, Inc.	Cystic Fibrosis-related Diabetes	11/25	03/26
NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations	Withdrawn	2	80	US	Sodium Fusidate, ACG-701, ARV-1801, Placebo	Aceragen	Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation	09/23	09/23
BMX-04-001, NCT05010577 / 2022-003810-35: Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection	Active, not recruiting	1b/2a	32	Europe, US, RoW	BX004-A, Bacteriophage, Placebo, Vehicle buffer	BiomX, Inc., BiomX Ltd.	Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis	10/23	03/24
Shaeffer, Cindy
No trials found